Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1982-12-16
pubmed:abstractText
Candida albicans isolates from 402 patients with no prior history of treatment with 5-fluorocytosine were collected at five medical centers from different areas of the United States. Isolates could be separated into four groups based on their minimum inhibitory concentrations (MICs) to 5-fluorocytosine. Group I isolates (60%) had MICs less than or equal to 12.5 micrograms/ml after 7 days, whereas groups II (22%), III (14%), and IV (4%) demonstrated MICs greater than 12.5 micrograms/ml on days 7, 2, and 1, respectively. Serotypes A and B accounted for 50.7 and 49.3%, respectively, of the 398 isolates typed. Serotype B was less prevalent in group I (26%), but predominated in the more resistant groups, groups II (85%), III (86%), and IV (53%). The common practice of identifying as "resistant" those isolates with MICs greater than 12.5 micrograms/ml after 48 h of incubation would yield a resistance rate in the United States of 11.5 to 15.5% in four centers and 35% in the fifth. Although serotype B and small agar disk diffusion zone sizes correlated with poor 5-fluorocytosine susceptibility, their ability to predict tube dilution MICs was limited. The true predictive value of such tests awaits correlation with in vivo studies.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-1108732, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-13905171, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-320931, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-325150, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-352220, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-374653, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4372272, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4565443, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4574129, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4580062, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4799552, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-4842332, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-5000267, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-568910, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-5797940, http://linkedlifedata.com/resource/pubmed/commentcorrection/6753737-984806
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
482-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.
pubmed:publicationType
Journal Article